What diseases is Militizumab mainly suitable for?

Milikizumab(Mirikizumab) is a targeted immunotherapy drug that has received widespread attention in recent years. It is mainly used to treat moderately to severely active Ulcerative Colitis(Ulcerative Colitis, referred to as UC). Ulcerative colitis is a chronic, relapsing inflammatory bowel disease (IBD) with clinical symptoms including diarrhea, abdominal pain, bloody stools and weight loss, which seriously affects the patient's quality of life. Militizumab, as a new generation of targeted immunosuppressants, can control intestinal mucosal inflammation and improve the condition by specifically blocking inflammatory pathways.

In recent years, because traditional treatments such as aminosalicylic acids, glucocorticoids, and immunosuppressants have limited efficacy or have many adverse reactions in some patients, more and more patients and doctors are turning their attention to biological agents. Milizumab is an innovative antibody drug developed in response to this demand. It targets the p19 subunit of interleukin-23 (IL-23), which is one of the key factors in regulating inflammatory responses. The sustained activation of IL-23 is closely related to a variety of autoimmune diseases, especially playing an important role in ulcerative colitis and Crohn's disease.

In addition to ulcerative colitis, militizumab has also been widely studied for the treatment of Crohn's Disease (Crohn's Disease), another major inflammatory bowel disease that also involves chronic inflammation of the intestine and has a high morbidity rate. Clinical research data for Crohn's disease are gradually accumulating. There is preliminary evidence that militizumab has the potential to induce and maintain remission in Crohn's disease, which also provides theoretical support for its future indication expansion.

In addition, militizumab has also been studied in basic and clinical studies in other diseases. Since theIL-23 pathway also plays an important role in the pathogenesis of psoriasis, IL-23 inhibitors represented by militizumab have shown good efficacy and tolerability in the treatment of moderate to severe plaque psoriasis. Although the approval of indications for psoriasis has not been widely popularized, relevant research results show that this direction has broad prospects.

Reference materials:https://omvoh.lilly.com/